[A case of drug-induced immune hemolytic anemia during alpha-interferon therapy for renal cell carcinoma].
A Case of drug-induced immune hemolytic anemia during alpha-interferon (alpha-IFN) therapy for renal cell carcinoma is reported. A 61-year-old woman was admitted to Tochigi cancer center for the treatment of left renal cell carcinoma. She underwent left radical nephrectomy. From 7th post operative day, alpha-IFN (6 x 10(6) IU) was administered every other day. Diclofenac and indomethacin were administered for pain and high fever induced by alpha-IFN. Hemoglobinuria was first noted on 20th post operative day. Immune hemolytic anemia was suspected by blood examinations including Coombs' test, serum haptoglobin, serum LDH and serum GOT. alpha-IFN therapy and administration of diclofenac and indomethacin were discontinued and prednisolone therapy (50 mg daily) was begun. Hemoglobinuria disappeared by 5 days and laboratory data became in normal range by 3 weeks. Drug-induced immune hemolytic anemia was diagnosed by the process of laboratory data, especially of direct Coombs' test. Though drug-induced immune hemolytic anemia is a rare adverse side effect during alpha-INF therapy for renal cell carcinoma, it seemed an important complication.
Yanaihara
H
H
Department of Urology, Tochigi Cancer Center, Japan.
Nakazono
M
M
Tsunoda
S
S
D000744:Anemia, Hemolytic, Autoimmune / Q000188:drug therapy / Q000209:etiology*; D002292:Carcinoma, Renal Cell / Q000628:therapy*; D004008:Diclofenac / Q000009:adverse effects; D005260:Female; D006801:Humans; D007213:Indomethacin / Q000009:adverse effects; D016898:Interferon-alpha / Q000009:adverse effects*; D007680:Kidney Neoplasms / Q000628:therapy*; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage
D016898:Interferon-alpha; D004008:Diclofenac; D011239:Prednisolone; D007213:Indomethacin